5,435
Views
110
CrossRef citations to date
0
Altmetric
Research Article

Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats

, , , , , , , , , , & show all
Pages 460-467 | Received 15 Nov 2013, Accepted 20 Jan 2014, Published online: 14 Feb 2014

References

  • Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29–45
  • de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:323–55
  • Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13–25
  • Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6:539–46
  • Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 2009;9:1519–27
  • Dickson PI. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol Ther 2009;47:S124–7
  • Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555–8
  • Gaillard PJ, Visser CC, de Boer M, et al. Blood-to-brain drug delivery using nanocarriers. In: Hammarlund-Udenaes M, de Lange ECM, Thorne R, eds. Drug delivery to the brain – physiological concepts, methodologies and approaches. Chapter 15. New York: Springer; 2014:433–54
  • Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011;8:683–700
  • Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10:73–9
  • Pinzon-Daza ML, Campia I, Kopecka J, et al. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab 2013;14:625–40
  • Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today 2012;17:367–78
  • Zlokovic BV, Mackic JB, McComb JG, et al. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 1994;201:402–8
  • Kannan R, Kuhlenkamp JF, Jeandidier E, et al. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990;85:2009–13
  • Kannan R, Chakrabarti R, Tang D, et al. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 2000;852:374–82
  • Gaillard PJ, Appeldoorn CCM, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2014;9:e82331
  • Gaillard PJ, Appeldoorn CC, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 2012;164:364–9
  • Lindqvist A, Rip J, Gaillard PJ, et al. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. Mol Pharm 2013;10:1533–41
  • Mdzinarishvili A, Sutariya V, Talasila PK, et al. Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res 2013;3:309–17
  • Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 2011;19:837–45
  • Chen RF, Knutson JR. Mechanism of fluorescence concentration quenching of carboxyfluorescein in liposomes: energy transfer to nonfluorescent dimers. Anal Biochem 1988;172:61–77
  • Roux F, Durieu-Trautmann O, Chaverot N, et al. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol 1994;159:101–13
  • Gaillard PJ, Leyssen P, Appeldoorn CCM, et al. Development of brain-targeted liposomes with antiviral drugs for treating lethal viral encephalitis. [Abstract] Paper presented at the 8th International Conference on Cerebral Vascular Biology (CVB); 2009 Jun 28–July 2; Sendai, Japan
  • Rip J, Appeldoorn CCM, Manca FM, et al. Receptor-mediated delivery of drugs across the blood-brain barrier. Pharmacology and Toxicology of the Blood-Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. Brussels, Belgium; 2010. doi: 10.3389/conf.fphar.2010.02.00025
  • Allen TM, Hansen CB, Guo LS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1993;1150:9–16
  • Chang T, Olson JA, Proffitt RT, Adler-Moore JP. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B. Med Mycol 2010;48:430–5
  • Rosa P, Clementi F. Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration. Pharmacology 1983;26:221–9
  • Haber E, Afergan E, Epstein H, et al. Route of administration-dependent anti-inflammatory effect of liposomal alendronate. J Control Release 2010;148:226–33